S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
Titel:
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
Auteur:
Yamada, Y. Denda, T. Gamoh, M. Iwanaga, I. Yuki, S. Shimodaira, H. Nakamura, M. Yamaguchi, T. Ohori, H. Kobayashi, K. Tsuda, M. Kobayashi, Y. Miyamoto, Y. Kotake, M. Shimada, K. Sato, A. Morita, S. Takahashi, S. Komatsu, Y. Ishioka, C.